Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2024;35(1):66-72
Article Links
State of the Art Review on the Treatment of Psoriatic Disease
Eleftherios Pelechas1, Evripidis Kaltsonoudis1, Michalis P. Migkos1, Nikolaos Koletsos1, Panagiota G. Karagianni2, Alexandros A. Drosos1, Paraskevi V. Voulgari1
Authors Information

Eleftherios Pelechas1, Evripidis Kaltsonoudis1, Michalis P. Migkos1, Nikolaos Koletsos1, Panagiota G. Karagianni2, Alexandros A. Drosos1, Paraskevi V. Voulgari1

1Department of Rheumatology, Medical School, University of Ioannina, Ioannina, Greece

2Department of Microbiology, Medical School, University of Ioannina, Ioannina, Greece

 
E Pelechas, E Kaltsonoudis, MP Migkos, N Koletsos, PG Karagianni, AA Drosos, PV Voulgari

Keywords: psoriasis, psoriatic arthritis, psoriatic disease, JAK inhibitors, IL inhibitors, TYK inhibitors
References
  1. World Health Organization psoriasis. Global report on. Glob Rep Psoriasis [Internet]. 2016;978. Available from: http://www.who.int/about/licensing/copyright_form/index.html%0Ahttp://www.who.int/about/licensing/
  2. Pelechas E, Kaltsonoudis E, Voulgari PV, Drosos AA. Psoriatic Arthritis. In: Illustrated Handbook of Rheumatic and Musculo-Skeletal Diseases. Springer, Cham, 2019. https://doi.org/10.1007/978-3-030-03664-5_5
  3. Alamanos Y, Pelechas E, Voulgari PV, Drosos AA. Incidence of spondyloarthritis and its subtypes: a systematic review. Clin Exp Rheumatol 2021;39(3):660-7. doi: 10.55563/clinexperheumatol/yycy0o.
  4. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med.2017;376(10):957–70.
  5. Cigolini C, Fattorini F, Gentileschi S, Terenzi R, Carli L. Psoriatic arthritis: one year in review 2022. Clin Exp Rheumatol 2022;40(9).
  6. Fragoulis GE, Evangelatos G, Tentolouris N, Fragkiadaki K, Panopoulos S, Konstantonis G, et al. Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. Ther Adv Musculoskelet Dis 2020;12:1759720X20976975. doi: 10.1177/1759720X20976975
  7. Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol 2017;10(8):899–910.
  8. Gialouri CG, Evangelatos G, Fragoulis GE. Choosing the appropriate target for the treatment of psoriatic arthritis: TNFα, IL-17, IL-23 or JAK inhibitors? Mediterr J Rheumatol 2022;33(Suppl 1):150-61.
  9. Magee C, Jethwa H, FitzGerald OM, Jadon DR. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. Ther Adv Musculoskelet Dis 2021;13.
  10. Schett G. Apremilast in psoriatic arthritis. Clin Exp Rheumatol 2015;33(5 Suppl 93):S98-100.
  11. Gossec L, Baraliakos X, Kerschbaumer A, De Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79(6):S700–12.
  12. Tahir H, Grewal S. Current unmet needs and emerging novel pharmacotherapies in psoriatic arthritis. Expert Opin Pharmacother 2022;23(4):417–20.
  13. Gialouri CG, Evangelatos G, Zhao SS, Kouna K, Karamanakos A, Iliopoulos A, et al. Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients' perception? Clin Exp Rheumatol 2023;41(1):159-65.
  14. Singh S, Facciorusso A, Singh AG, Casteele N Vande, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One 2018;13(5).
  15. Stober C, Ye W, Guruparan T, Htut E, Clunie G, Jadon D. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Rheumatology (Oxford) 2018;57(1):158–63.
  16. Costa L, Perricone C, Chimenti MS, Puente AD, Caso P, Peluso R, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D 2017;17(4):509-522.
  17. Alten R, Conaghan PG, Strand V, Sullivan E, Blackburn S, Tian H, et al. Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study. Clin Rheumatol 2019;38(6):1615–26.
  18. Ariani A, Santilli D, Mozzani F, Lumetti F, Lucchini G, Di Donato E, et al. Cycling or swap biologics and small molecules in psoriatic arthritis: Observations from a real-life single center cohort. Medicine (Baltimore) 2021;100(16):e25300.
  19. Zardin-Moraes M, Da Silva ALFA, Saldanha C, Kohem CL, Coates LC, Henrique LR, et al. Prevalence of Psoriatic Arthritis Patients Achieving Minimal Disease Activity in Real-world Studies and Randomized Clinical Trials: Systematic Review with Metaanalysis. J Rheumatol 2020;47(6):839–46.
  20. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res 2019;71(1):2–29.
  21. Coates LC, Corp N, van der Windt DA, Soriano ER, Kavanaugh A. GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting. J Rheumatol 2021;97:65–6.
  22. Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford) 2019;58(2):336–44.
  23. O’Brien-Gore C, Gray EH, Durham LE, Taams LS, Kirkham BW. Drivers of Inflammation in Psoriatic Arthritis: the Old and the New. Curr Rheumatol Rep 2021;23(6).
  24. Busse K, Liao W. Which psoriasis patients develop psoriatic arthritis? Psoriasis Forum 2010;16(4):17-25
  25. Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol 2010;24 Suppl 2:31-5.
  26. Sieper J, Poddubnyy D, Miossec P. The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 2019;15(12):747–57.
  27. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013;72(5):736-740.
  28. Wilson F, Icen M, Crowson C, McEvoy M, Gabriel S, Kremers H. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009;61(2):233-239.
  29. Soltani-Arabshahi R, Wong B, Feng B, Goldgar D, Duffin K, Krueger G. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 2010;146(7):721-726).
  30. Eder L, Law T, Chandran V, Shanmugarajah S, Shen H, Rosen CF, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken) 2011;63(8):1091-7.
  31. Wu S, Cho E, Li WQ, Han J, Qureshi AA. Alcohol intake and risk of incident psoriatic arthritis in women. J Rheumatol 2015;42(5):835-40.
  32. Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med 2017;377(16):1537–50.
  33. McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med 2021;384(13):1227–39.
  34. Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van Den Bosch F, Tsuji S, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 2021;80(3):312–20.
  35. Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet (London, England) 2018;392(10162):2367–77.
  36. Mease PJ, Deodhar AA, Van Der Heijde D, Behrens F, Kivitz AJ, Neal J, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815–22.
  37. Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet (London, England) 2020;395(10230):1115–25.
  38. Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet (London, England) 2020;395(10230):1126–36.
  39. Mease PJ, McInnes IB, Tam LS, Eaton K, Peterson S, Schubert A, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford) 2021;60(5):2109–21.
  40. Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis 2021;80(9):1147–57.
  41. Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis 2022;81(2):225–31.
  42. Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, et al. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. J Am Acad Dermatol 2021;85(3):572–81.
  43. McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet (London, England) 2020;395(10235):1496–505.
  44. Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 2017;389(10086):2317–27.
  45. Coates LC, McInnes IB, Merola JF, Warren RB, Kavanaugh A, Gottlieb AB, et al. Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study. Arthritis Rheumatol (Hoboken, NJ) 2022;
  46. Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet (London, England) 2020;395(10222):427–40.
  47. Mease PJ, Helliwell PS, Hjuler KF, Raymond K, Mcinnes I. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis 2021;80(2):185–93.